Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome

Annals of Hematology

Volumn 84, Issue 3, 2005, Pages 167-176

  Spiriti, M A Aloe ^a   Latagliata, R ^b   Niscola, P ^c   Cortelezzi, A ^d   Francesconi, M ^e   Ferrari, D ^f   Volpe, E ^g   Clavio, M ^h   Grossi, A ⁱ   Reyes, M Tambone ^j   Musto, P ^k   Mitra, M E ^l   Azzara A ^m   Pagnini, D ⁿ   D'Arena, G ^o   Spadano, A ^p   Balleari, E ^q   Pecorari, P ^r   Capochiani, E ^s   De Biasi, E ^t   Perego, D ^u   Monarca, B ^a   Pisani, F ^v   Scaramella, G ^w   Petti, M C ^v   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Divisione Ematologia   (Italy)

^c Ospedale di Montefiascone   (Italy)

^d Policlinico di Milano   (Italy)

^e Azienda RM/H   (Italy)

^f Med Unita Operativa di Ematologia   (Italy)

^g S G MOSCATI HOSPITAL   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j Serv Assistenza Ematol e Oncologia   (Italy)

^k Divisione di Ematologia   (Italy)

^l UNIVERSITY OF PALERMO   (Italy)

^m UNIVERSITY OF PISA   (Italy)

ⁿ ASL CE/1   (Italy)

^o Azienda Osp S G di Dio/R Aragona   (Italy)

^p SPIRITO SANTO HOSPITAL   (Italy)

^q UNIVERSITY OF GENOA   (Italy)

^r MAGGIORE HOSPITAL   (Italy)

^s Livorno Hospital   (Italy)

^t OSPEDALE CA FONCELLO   (Italy)

^u DESIO HOSPITAL   (Italy)

^v REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^w Ospedale San Polo   (Italy)

more..

Author keywords

Anemia; Epoetin; Fatigue; Myelodysplastic syndrome; Quality of life

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DERMATITIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; FEMALE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; QUESTIONNAIRE; RASH; RISK ASSESSMENT; SCORING SYSTEM; TACHYCARDIA;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; QUESTIONNAIRES; RISK;

EID: 13844313807     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0961-9     Document Type: Article

References (41)

1. Bowen DT, Hellstrom-Lindberg E (2001) Best supportive care for anaemia of myelodysplasia: Inclusion of recombinant erythropoietin therapy? Leuk Res 25:19-21 10.1016/S0145-2126(00)00100-4
2. Casadevall N (1998) Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Semin Oncol 25 [3 Suppl 7]:12-18 1:CAS:528:DyaK1cXkvVektLc%3D
3. Ludwig H, Fritz E (1998) Anemia of cancer patients: Patient selection and patient stratification for epoetin treatment. Semin Oncol 25 [3 Suppl 7]:35-38 1:STN:280:DyaK1czjsVCjsQ%3D%3D
4. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25 [3 Suppl 7]:43-46 1:STN:280:DyaK1czjsVCjtw%3D%3D
5. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995) The use of r-HuEpo in the treatment of aneamia related to myelodysplasia (MDS). Br J Haematol 89:831-837 1:STN:280:ByqB1M%2FktVU%3D
6. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103:1070-1074
7. Demetri GD, Kris M, Wade J, Degos L, Cella D, for the Procrit Study Group (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16:3412-3425 1:CAS:528:DyaK1cXmvFGrur0%3D
8. Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172-179 10.1046/j.1365-2141.2001.02715.x
9. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhom LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882 1:CAS:528:DC%2BD3MXltVGgs7Y%3D
10. Littlewood RJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874 1:CAS:528:DC%2BD3MXltVGgs7k%3D
11. Rizzo DJ, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and American Society of Hematology. Blood 100:2303-2321 10.1182/blood-2002-06-1767
12. Bowen D, Culligan D, Jowitt S et al (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120:187-200 10.1046/j.1365-2141.2003.03907.x
13. Alessandrino EP, Amadori S, Barosi G et al (2002) Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 87:1286-1306 12495903
14. Cheung W, Minton N, Gunawardena K (2001) Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 57:411-418 10.1007/s002280100324
15. Cella D (1997) The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 [Suppl 2]:13-19 1:STN:280:ByiA1MjptlY%3D
16. Cheson B, Bennett JM, Kantarjian H et al (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674 1:CAS:528:DC%2BD3cXosVGnt7o%3D
17. Cella D (1997) FACIT manual: Manual of the functional assessment of chronic illness therapy (FACIT) scales. Version 4, Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, Evanston, IL
18. Simes J, Greatorex V, Gebski VJ (1998) Practical approaches to minimize problems with missing quality of life data. Stat Med 17:725-737
19. Hollen PJ, Gralla RJ, Cox C, Eberly SW, Kris MG (1997) A dilemma in analysis: Issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung Cancer 18:119-136 10.1016/S0169-5002(97)00059-7
20. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glapsy J (2002) Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer 3:180-190 14662041
21. Fallowfield L, Gagnon D, Zagari M et al (2002) Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 87:1341-1353 10.1038/sj.bjc.6600657
22. Hellström-Lindberg E, Gulbrandsen N, Lindberg G et al (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 120:1037-1046 12648074
23. Casadevall N, Durieux P, Dubois S et al (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 104:321-327 10.1182/blood-2003-07-2252
24. Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J, for the Epoetin Alfa Study Group (2003) Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 39:335-345 10.1016/S0959-8049(02)00628-7
25. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anaemia and fatigue scales. J Pain Symptom Manage 24:547-561 10.1016/S0885-3924(02)00529-8
26. Cella D, Hahn EA, Dineen K (2002) Meaningful change in cancer-specific quality of life score: Differences between improvement and worsening. Qual Life Res 11:207-221 10.1023/A:1015276414526
27. Dancey J, Zee B, Osoba D et al (1997) Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res 6:151-158 10.1023/A:1026442201191
28. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer. A systematic, quantitative review. Cancer 9:2214-2221 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.3.CO;2-G
29. Wallwik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R (2002) Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 68:180-186 10.1034/j.1600-0609.2002.01530.x
30. Rigolin GM, Della Porta M, Bigoni R et al (2002) RHuEPO administration in patients with low-risk myelodysplastic syndromes: Evaluation of erythroid precursor response by fluorescence in situ hybridisation on May-Grunwald-Giemsa-stained bone marrow samples. Br J Haematol 119:652-659 10.1046/j.1365-2141.2002.03867.x
31. Terpos E, Mongiou A, Kouraklis A et al (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: A phase II trial in 281 patients. Br J Haematol 118:174-180 10.1046/j.1365-2141.2002.03583.x
32. Hellström-Lindberg E (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67-71 7833279
33. Musto P, Sanpaolo G, D'Arena G et al (2001) Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 86:44-51 1:CAS:528:DC%2BD3MXhsFGksb8%3D
34. Kasper C, Zahner J, Sayer HG (2002) Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol 128:497-502 10.1007/s00432-002-0372-z
35. Remacha AF, Arrizabalaga B, Villegas A et al (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica 84:1058-1064 1:CAS:528:DC%2BD3cXhtV2rs70%3D
36. Mantovani L, Lentini G, Hentschel B et al (2000) Treatment of anemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 109:367-385 10.1046/j.1365-2141.2000.02016.x
37. Tehranchi R, Fadeel B, Forsblom A et al (2003) Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101:1080-1086 10.1182/blood-2002-06-1774
38. Grossi A, Musto P, Santini V et al (2002) Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica 87:322-323 11869946
39. Tsiara SN, Kapsali HD, Panteli K et al (2001) Preliminary results of amifostine administration in combination with recombinant erythropoietin in patients with myelodysplastic syndromes. J Exp Clin Cancer Res 20:35-38 1:CAS:528:DC%2BD3MXkt1Gjurs%3D
40. Stasi R, Brunetti M, Terzoli E, Amadori S (2002) Substained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 99:1578-1584 10.1182/blood.V99.5.1578
41. Cortelezzi A, Cattaneo C, Sarina B et al (2000) Efficacy of N-acetylcysteine and all-trans retinoic acid in restoring in vitro effective hemopoiesis in myelodysplastic syndromes. Leuk Res 24:129-137 10.1016/S0145-2126(99)00165-4